LSD1 is Required for Euchromatic Origin Firing and Replication Timing
Overview
Pharmacology
Authors
Affiliations
The chromatin-based rule governing the selection and activation of replication origins remains to be elucidated. It is believed that DNA replication initiates from open chromatin domains; thus, replication origins reside in open and active chromatin. However, we report here that lysine-specific demethylase 1 (LSD1), which biochemically catalyzes H3K4me1/2 demethylation favoring chromatin condensation, interacts with the DNA replication machinery in human cells. We find that LSD1 level peaks in early S phase, when it is required for DNA replication by facilitating origin firing in euchromatic regions. Indeed, euchromatic zones enriched in H3K4me2 are the preferred sites for the pre-replicative complex (pre-RC) binding. Remarkably, LSD1 deficiency leads to a genome-wide switch of replication from early to late. We show that LSD1-engaged DNA replication is mechanistically linked to the loading of TopBP1-Interacting Checkpoint and Replication Regulator (TICRR) onto the pre-RC and subsequent recruitment of CDC45 during origin firing. Together, these results reveal an unexpected role for LSD1 in euchromatic origin firing and replication timing, highlighting the importance of epigenetic regulation in the activation of replication origins. As selective inhibitors of LSD1 are being exploited as potential cancer therapeutics, our study supports the importance of leveraging an appropriate level of LSD1 to curb the side effects of anti-LSD1 therapy.
Inhibition of LSD1 via SP2509 attenuated the progression of rheumatoid arthritis.
Yu Z, Li P, Gao D, Hu Y, Xia F, Liu L Immunol Res. 2024; 72(4):797-810.
PMID: 38722530 DOI: 10.1007/s12026-024-09486-5.
CDC45 promotes the stemness and metastasis in lung adenocarcinoma by affecting the cell cycle.
Liu Y, Han T, Xu Z, Wu J, Zhou J, Guo J J Transl Med. 2024; 22(1):335.
PMID: 38589907 PMC: 11000299. DOI: 10.1186/s12967-024-05038-5.
Strategies that regulate LSD1 for novel therapeutics.
Li M, Dai M, Cheng B, Li S, Guo E, Fu J Acta Pharm Sin B. 2024; 14(4):1494-1507.
PMID: 38572094 PMC: 10985039. DOI: 10.1016/j.apsb.2024.01.005.
Papadopoulou G, Petroulia S, Karamichali E, Dimitriadis A, Marousis D, Ioannidou E Cells. 2023; 12(21).
PMID: 37947646 PMC: 10648375. DOI: 10.3390/cells12212568.
Ma J, Zhou Y, Pan P, Yu H, Wang Z, Li L Nat Commun. 2023; 14(1):1810.
PMID: 37002234 PMC: 10066190. DOI: 10.1038/s41467-023-37499-5.